Retrospective review of intermittent and continuous infusion vancomycin for methicillin-resistant Staphylococcus aureus bacteremia
European Journal of Clinical Pharmacology · 2024
DOI: 10.1007/s00228-023-03585-2 ↗Kurz gefasst
Fachartikel in der Zeitschrift European Journal of Clinical Pharmacology, 2024. Verfasst von Diari Gilliam und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy, University of New Mexico Hospitals, 2211 Lomas Blvd NE, Albuquerque, NM, 87106, USA. dngilliam@salud.unm.edu. Hauptthemen laut MEDLINE: Methicillin-Resistant Staphylococcus aureus, Staphylococcal Infections, Bacteremia. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 18 Literaturangaben.
Abstract (Originalsprache)
PURPOSE: Vancomycin is commonly administered as an intermittent infusion (IIV), although vancomycin's stability at room temperature permits administration continuously over 24 h (CIV). At our institution, CIV has been the preferred infusion method for over 20 years due to ease of administration and simplicity of therapeutic drug monitoring. The purpose of this study was to examine the outcomes associated with IIV compared to CIV. METHODS: This was a retrospective study of patients who received vancomycin for MRSA bacteremia. The primary outcomes were the time to therapeutic goal and frequency of adverse drug reactions on IIV compared to CIV. Secondary outcomes evaluated all-cause readmission, relapse, and mortality 30 days after completion of therapy. RESULTS: Sixty-three patients were included. Significantly fewer patients were able to achieve a therapeutic goal on IIV compared to CIV (52.4% vs. 82.5%, p < 0.01). Patients on IIV took 3.6 days, on average, to reach the target goal, compared to 1.9 days when patients were switched to CIV (95% confidence interval, 0.48-3.04, p < 0.01). Six patients experienced adverse events on IIV, and 15 patients experienced adverse events on CIV (IIV 9.5%, CIV 23.8%, p = 0.035). One patient experienced relapse of infection, and six patients (9.5%) were readmitted 30 days after completion of therapy. There were no deaths in the cohort. CONCLUSION: For MRSA bacteremia, CIV enabled patients to achieve the AUC/MIC goal significantly faster than when patients received IIV. Furthermore, patients who were unable to achieve a therapeutic trough on IIV became therapeutic once switched to CIV.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmacy, University of New Mexico Hospitals, 2211 Lomas Blvd NE, Albuquerque, NM, 87106, USA. dngilliam@salud.unm.edu.
- Department of Pharmacy, Presbyterian Healthcare Services, Albuquerque, NM, 87106, USA.
- Division of Infectious Diseases, Department of Internal Medicine, University of Iowa Hospitals and Clinics, Iowa City, IA, 52242, USA.
- Department of Pharmacy, University of New Mexico Hospitals, 2211 Lomas Blvd NE, Albuquerque, NM, 87106, USA.
Zitieren
APA
Gilliam, D., Acosta, D., Carvour, M. L., & Walraven, C. (2024). Retrospective review of intermittent and continuous infusion vancomycin for methicillin-resistant Staphylococcus aureus bacteremia. European Journal of Clinical Pharmacology. https://doi.org/10.1007/s00228-023-03585-2
Vancouver
Gilliam D, Acosta D, Carvour ML, Walraven C. Retrospective review of intermittent and continuous infusion vancomycin for methicillin-resistant Staphylococcus aureus bacteremia. European Journal of Clinical Pharmacology. 2024. doi:10.1007/s00228-023-03585-2
BibTeX
@article{Gilliam2024,
author = {Gilliam, Diari and Acosta, Dominic and Carvour, Martha L and Walraven, Carla},
title = {Retrospective review of intermittent and continuous infusion vancomycin for methicillin-resistant Staphylococcus aureus bacteremia},
journal = {European Journal of Clinical Pharmacology},
year = {2024},
doi = {10.1007/s00228-023-03585-2}
}
EUVIMED